Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Hoffmann

Showing results (101-110 of 144) with videos related to

Pageof 15
Sort By:
Elife|September 13, 2017
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysisTeja Turk, Nadine Bachmann, Claus Kadelka, et al.
JAAD International|February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Gut|July 28, 2010
Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapyJanine Rohrbach, Nicola Robinson, Gillian Harcourt, et al.
Medicine|January 13, 2017
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretroviralsMohaned Shilaih, Alex Marzel, Dominique L Braun, et al.
Current Infectious Disease Reports|April 29, 2015
The swiss transplant cohort study: lessons from the first 6 yearsChristoph Berger, Pierre-Yves Bochud, Katja Boggian, et al.
Current Biology : CB|February 13, 2007
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivoMartin Steegmaier, Matthias Hoffmann, Anke Baum, et al.
Mbio|August 28, 2025
Inflammation and B cell activation define a plasma proteome signature predicting tuberculosis in people with HIVKatharina Kusejko, Mohammad Arefian, Diane Duroux, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2018
Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort StudySelene Leon-Reyes, Juliane Schäfer, Mathias Früh, et al.
The Journal of Infectious Diseases|February 22, 2015
The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected IndividualsMolly R Perkins, Istvan Bartha, J Katherina Timmer, et al.
Open Forum Infectious Diseases|June 6, 2018
The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic AnalysisAlex Marzel, Katharina Kusejko, Rainer Weber, et al.
Pageof 15

Showing results (101-110 of 144) with videos related to

Sort By:
Pageof 15
Elife|September 13, 2017
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysisTeja Turk, Nadine Bachmann, Claus Kadelka, et al.
JAAD International|February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Gut|July 28, 2010
Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapyJanine Rohrbach, Nicola Robinson, Gillian Harcourt, et al.
Medicine|January 13, 2017
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretroviralsMohaned Shilaih, Alex Marzel, Dominique L Braun, et al.
Current Infectious Disease Reports|April 29, 2015
The swiss transplant cohort study: lessons from the first 6 yearsChristoph Berger, Pierre-Yves Bochud, Katja Boggian, et al.
Current Biology : CB|February 13, 2007
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivoMartin Steegmaier, Matthias Hoffmann, Anke Baum, et al.
Mbio|August 28, 2025
Inflammation and B cell activation define a plasma proteome signature predicting tuberculosis in people with HIVKatharina Kusejko, Mohammad Arefian, Diane Duroux, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2018
Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort StudySelene Leon-Reyes, Juliane Schäfer, Mathias Früh, et al.
The Journal of Infectious Diseases|February 22, 2015
The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected IndividualsMolly R Perkins, Istvan Bartha, J Katherina Timmer, et al.
Open Forum Infectious Diseases|June 6, 2018
The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic AnalysisAlex Marzel, Katharina Kusejko, Rainer Weber, et al.
Pageof 15